<DOC>
	<DOCNO>NCT00518219</DOCNO>
	<brief_summary>The purpose study ass efficacy TW compare Valsartan treatment heavy proteinuria membranous nephropathy .</brief_summary>
	<brief_title>To Compare Efficacy Safety Tripterygium Wilfordii ( TW ) Versus Valsartan Membranous Nephropathy ( MN )</brief_title>
	<detailed_description>Membranous nephropathy heavy proteinuria high risk progress CRF . Tripterygium ( TW ) Chinese traditional patent drug , reduce proteinuria chronic glomerular nephritis , IgA nephropathy . So , design randomize , prospective clinical trial ass efficacy safety TW versus Valsartan treatment heavy proteinuria MN .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Biopsyproven idiopathic membranous nephropathy Nephrotic syndrome proteinuria ( &gt; 4 g/day ) serum albumin &lt; 30 g/dl Age 18 informed consent Patient abnormal liver function test Prior therapy sirolimus , CSA , MMF , tacrolimus azathioprin , chlorambucil , levamisole , methotrexate , nitrogen mustard last 90 day , Active/serious infection , Patient hepatitis B surface antigen hepatitis C antibody positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>TW</keyword>
	<keyword>Valsartan</keyword>
	<keyword>treatment</keyword>
	<keyword>membranous nephropathy</keyword>
	<keyword>proteinuria</keyword>
</DOC>